Psyence Biomedical Ltd. has regained Nasdaq compliance following a market transfer and successful share consolidation.
Quiver AI Summary
Psyence Biomedical Ltd. announced that it has regained compliance with Nasdaq's continued listing requirements, as confirmed by the Nasdaq Hearings panel. Following a transfer to The Nasdaq Capital Market on November 15, 2024, the company met the minimum market and stockholder equity requirements. Additionally, a 75-for-1 share consolidation, effective November 26, 2024, led to its shares trading above the $1 minimum bid price for 18 consecutive days. CEO Dr. Neil Maresky expressed gratitude for this compliance, highlighting the company’s favorable financial position, with no debt and $5.6 million in cash, and readiness to proceed with its business plan and clinical trials. Psyence focuses on developing nature-derived psilocybin-based therapeutics for mental health disorders and emphasizes its commitment to evidence-based innovation.
Potential Positives
- Psyence Biomedical Ltd. has regained compliance with all Nasdaq continued listing requirements, which enhances its credibility and market presence.
- The successful transfer to The Nasdaq Capital Market demonstrates the company's adaptive strategy to meet necessary financial thresholds.
- The implementation of a 75-for-1 share consolidation has allowed the company's shares to trade above the $1 minimum bid price requirement, ensuring compliance and stability in trading.
- The company’s current cash position of $5.6 million, alongside a debt-free balance sheet, positions it well to execute on its business plan and clinical trials.
Potential Negatives
- The company has had to transfer its listing to the Nasdaq Capital Market, indicating it did not meet the requirements to remain on the Nasdaq Global Market, which may raise concerns about its financial stability.
- The significant share consolidation (75-for-1) may signal to investors that the company's stock price was low, potentially undermining confidence in the company's market performance.
- The press release contains numerous forward-looking statements about future performance that are contingent on successful outcomes of ongoing clinical trials, raising concerns about the uncertainties and risks inherent in their business model.
FAQ
What recent compliance achievement has Psyence Biomedical made?
Psyence Biomedical has regained compliance with all applicable Nasdaq continued listing requirements.
When did Psyence Biomed transfer to The Nasdaq Capital Market?
The transfer to The Nasdaq Capital Market became effective on November 15, 2024.
What was the purpose of the 75-for-1 share consolidation?
The share consolidation was intended to address the $1 minimum bid price requirement from Nasdaq.
How is Psyence Biomed financially positioned after regaining compliance?
The company is debt-free with a cash position of $5.6 million, well-positioned to execute its business plan.
What focus does Psyence Biomedical have in its pharmaceutical development?
Psyence Biomedical focuses on developing nature-derived psilocybin-based psychedelic medicine for mental health disorders.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PBM Hedge Fund Activity
We have seen 8 institutional investors add shares of $PBM stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADVISORSHARES INVESTMENTS LLC added 769,334 shares (+166.1%) to their portfolio in Q3 2024
- CITADEL ADVISORS LLC added 169,251 shares (+inf%) to their portfolio in Q3 2024
- STONEHAGE FLEMING FINANCIAL SERVICES HOLDINGS LTD added 80,500 shares (+inf%) to their portfolio in Q3 2024
- JANE STREET GROUP, LLC added 45,963 shares (+inf%) to their portfolio in Q3 2024
- TOWER RESEARCH CAPITAL LLC (TRC) added 34,391 shares (+inf%) to their portfolio in Q3 2024
- MORGAN STANLEY added 28,407 shares (+142.0%) to their portfolio in Q3 2024
- COWEN AND COMPANY, LLC removed 25,000 shares (-100.0%) from their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has received notice from the Nasdaq Hearings panel that the Company has regained compliance with all applicable Nasdaq continued listing requirements.
As previously announced, Psyence Biomed requested to be transferred from The Nasdaq Global Market to The Nasdaq Capital Market, effective November 15, 2024. As a result of this transfer, the Company regained compliance with listing rules 5550(a)(5), the $1.0 million minimum market value of publicly held shares requirement, and 5550(b)(1), the $2.5 million minimum stockholders’ equity requirement.
Additionally, the Company obtained shareholder approval during its Annual General Meeting on November 12, 2024 to effect a 75-for-1 share consolidation. This share consolidation, which went into effect on November 26, 2024, was intended to address Nasdaq’s listing rule 5550(a)(2), the $1 minimum bid price requirement. As the Company’s shares have traded above $1 for the subsequent 18 trading days following the share consolidation, the minimum bid price requirement has been formally satisfied.
“We are grateful to the Nasdaq Hearings Panel for allowing us the opportunity to demonstrate compliance with all Nasdaq continued listing rules, and we are pleased to have achieved this goal,” stated Dr. Neil Maresky, M.B., B.Ch., Chief Executive Officer of Psyence Biomed. “With Nasdaq compliance, a debt free balance sheet and a cash position of $5.6 million, the Company is well positioned to execute its business plan and clinical trial, for which patient screening has commenced.”
About Psyence Biomed:
Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the world’s few vertically integrated biopharmas with a focus on psychedelic-based pharmaceutical therapeutics. The first life science biotechnology company developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq, Psyence is initially working to address the unmet needs of patients who suffer from mental health disorders in the context of Palliative Care. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, FDA-approved, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders.
Learn more at
www.psyencebiomed.com
and on
LinkedIn
.
Contact Information for Psyence Biomedical Ltd.
Email:
ir@psyencebiomed.com
Media Inquiries:
media@psyencebiomed.com
General Information:
info@psyencebiomed.com
Phone: +1 416-477-1708
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
Forward Looking Statements
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning.
Forward-looking statements in this communication include statements regarding the progress of the Phase IIb clinical trial and the achievement of trial milestones, and the regaining of compliance with all applicable Nasdaq continued listing requirements. These forward-looking statements are based on a number of assumptions, including the assumption that there will be no delays in the execution of the Phase IIb clinical trial implementation schedule, that topline data from this trial will be positive, and that the Company will effectively execute on its Nasdaq continued listing compliance plan. There can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements.
There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others: (i) delays in the execution of the Phase IIb trial; (ii) the ability of Psyence Biomed to maintain the listing of its common shares and warrants on Nasdaq; (iii) the ability to implement the Nasdaq compliance plan presented to the Panel
; and
(iv)
volatility in the price of the securities of Psyence Biomed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence Biomed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence Biomed’s business and changes in Psyence Biomed’s capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the Company’s Form 20-F filed with the Securities and Exchange Commission (the “SEC”) on July 29, 2024 and other documents filed by Psyence Biomed from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such information. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence Biomed does not intend to update these forward-looking statements.
The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
